Arvinas, Inc. (ARVN) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates.
Analysis Summary
Arvinas, Inc. reported revenue of $262.6M in the most recent fiscal year, growing at a 5-year CAGR of 58.9%.
Trailing-twelve-month margins: gross margin 96.4%, operating margin -4.5%, net margin 2.9%.
At the current price of $8.16, ARVN trades at a P/E of 39.84 and an ROE of 1.91%. Market capitalisation stands at $526M.
Balance sheet quality for ARVN: current ratio of 4.9, net cash position of $676.5M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $8.16 |
| Market Cap | $526M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 39.84 |
| Price / Book | 0.87 |
| EV / EBITDA | 164.10 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 1.91% |
| Return on Invested Capital | -2.18% |
| Return on Assets | 1.38% |
| Gross Margin | 96.43% |
| Operating Margin | -4.45% |
| Net Margin | 2.94% |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 7.91 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -0.75 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ARVN | Arvinas, Inc. | $526M | 39.84 | 0.87 | 1.9% |
| ERAS | Erasca, Inc. | $5.6B | 13.98 | -80.4% | |
| DAWN | Day One Biopharmaceuticals, Inc. | $2.2B | 5.05 | -23.4% | |
| IOVA | Iovance Biotherapeutics, Inc. | $4.1B | 6.04 | -40.5% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
Price Performance
| 1 month | -11.88% |
| 3 months | +6.39% |
| Year-to-date | -31.20% |
| 1 year | +7.23% |
| 3 years | -66.45% |
52-Week Range
| 52-week High | $14.51 |
| 52-week Low | $6.97 |
| Avg Volume (90d) | 822K |
Related companies: ATXS · AVBP · DAWN · DNA · ERAS · GERN · IOVA
Explore sector: Healthcare · Biotechnology
More sections of ARVN: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks